This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2012 Apr 23;172(8):668-70.

doi: 10.1001/archinternmed.2012.135.

Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer

Craig E Pollack¹, Gary Noronha, Gene E Green, Nrupen A Bhavsar, H Ballentine Carter

Affiliations

PMID: 22529237
PMCID: PMC3359062
DOI: 10.1001/archinternmed.2012.135

Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer

Craig E Pollack et al. Arch Intern Med. 2012.

. 2012 Apr 23;172(8):668-70.

doi: 10.1001/archinternmed.2012.135.

Authors

Craig E Pollack¹, Gary Noronha, Gene E Green, Nrupen A Bhavsar, H Ballentine Carter

Affiliation

¹ Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. cpollac2@jhmi.edu

PMID: 22529237
PMCID: PMC3359062
DOI: 10.1001/archinternmed.2012.135

No abstract available

PubMed Disclaimer

Figures

Figure 1
Percent of providers who state that the USPSTF draft recommendations will change their prostate specific antigen (PSA) screening practice according to how strongly they agree or disagree with the draft recommendations. The sample included providers who had previously heard of the draft recommendations (N=114).

See this image and copyright information in PMC

Similar articles

Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others.
Printz C. Printz C. Cancer. 2018 Jan 1;124(1):11-12. doi: 10.1002/cncr.31180. Cancer. 2018. PMID: 29251768 No abstract available.
Preventive Services Task Force recommends against PSA screening after age 75.
Twombly R. Twombly R. J Natl Cancer Inst. 2008 Nov 19;100(22):1571-3. doi: 10.1093/jnci/djn422. Epub 2008 Nov 11. J Natl Cancer Inst. 2008. PMID: 19001606 Free PMC article. No abstract available.
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J. Carlsson S, et al. J Clin Oncol. 2012 Jul 20;30(21):2581-4. doi: 10.1200/JCO.2011.40.4327. Epub 2012 Jun 18. J Clin Oncol. 2012. PMID: 22711853 Free PMC article. No abstract available.
Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS, Herlemann A, Washington SL 3rd, Cooperberg MR. Eapen RS, et al. Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383. Curr Opin Urol. 2017. PMID: 28221220 Review.
[Prostate Specific Antigen (PSA), yet how much damage?].
Braillon A, Hill C, Dubois G. Braillon A, et al. Presse Med. 2012 May;41(5):482-5. doi: 10.1016/j.lpm.2011.12.011. Epub 2012 Feb 14. Presse Med. 2012. PMID: 22336482 Review. French.

See all similar articles

Cited by

Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials.
Goodwin JS, Tan A, Jaramillo E, Kuo YF. Goodwin JS, et al. J Natl Cancer Inst. 2013 May 15;105(10):743-5. doi: 10.1093/jnci/djt039. Epub 2013 Mar 4. J Natl Cancer Inst. 2013. PMID: 23459245 Free PMC article.
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
Fleshner K, Carlsson SV, Roobol MJ. Fleshner K, et al. Nat Rev Urol. 2017 Jan;14(1):26-37. doi: 10.1038/nrurol.2016.251. Epub 2016 Dec 20. Nat Rev Urol. 2017. PMID: 27995937 Free PMC article. Review.
Linking physician attitudes to their breast cancer screening practices: A survey of US primary care providers and gynecologists.
Radhakrishnan A, Nowak SA, Parker AM, Visvanathan K, Pollack CE. Radhakrishnan A, et al. Prev Med. 2018 Feb;107:90-102. doi: 10.1016/j.ypmed.2017.11.010. Epub 2017 Nov 17. Prev Med. 2018. PMID: 29155227 Free PMC article.
Primary care physicians' use of an informed decision-making process for prostate cancer screening.
Volk RJ, Linder SK, Kallen MA, Galliher JM, Spano MS, Mullen PD, Spann SJ. Volk RJ, et al. Ann Fam Med. 2013 Jan-Feb;11(1):67-74. doi: 10.1370/afm.1445. Ann Fam Med. 2013. PMID: 23319508 Free PMC article.
Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
Shahangian S, Sharma KP, Fan L, Siegel DA. Shahangian S, et al. Cancer Rep (Hoboken). 2021 Aug;4(4):e1365. doi: 10.1002/cnr2.1365. Epub 2021 May 2. Cancer Rep (Hoboken). 2021. PMID: 33934557 Free PMC article.

See all "Cited by" articles

References

1. U.S. Preventive Services Task Force. Screening for Prostate Cancer: Draft Recommendation Statement. [Accessed December 7, 2011];AHRQ Publication No. 12-05160-EF-2. http://www.uspreventiveservicestaskforce.org/uspstf12/prostate/draftrec3....
1. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70–98. - PubMed
1. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182:2232–41. - PubMed
1. Linder SK, Hawley ST, Cooper CP, Scholl LE, Jibaja-Weiss M, Volk RJ. Primary care physicians’ reported use of pre-screening discussions for prostate cancer screening: a cross-sectional survey. BMC Fam Pract. 2009;10 doi: 10.1186/1471=2296-10-19. - DOI - PMC - PubMed
1. Drazer MW, Huo D, Schoenberg MA, Razmaria A, Eggener SE. Population-Based Patterns and Predictors of Prostate-Specific Antigen Screening Among Older Men in the United States. J Clin Oncol. 2011;29:1736–43. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information